NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult Subjects FARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…Original Article
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis
